El Hassane Sidibé

Diet and Longevity

• Broschiertes Buch

Produktbeschreibung

A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo group). In the planned primary analysis, which was performed after 378 events had occurred, median metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. Thefollowing adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%).

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: LAP LAMBERT Academic Publishing
• Seitenzahl: 284
• Erscheinungstermin: 6. November 2019
• Englisch
• Abmessung: 220mm x 150mm x 18mm
• Gewicht: 441g
• ISBN-13: 9786200466853
• ISBN-10: 6200466858
• Artikelnr.: 62453005

Autorenporträt

Monsieur El Hassane Sidibe, Médecin, Médaillé de la Société Médicale des Hôpitaux de Paris. Professeur titulaire d¿Endocrinologie, Académie des Sciences de New-York, Académie Européenne des Sciences, des Arts et des Lettres.